|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication October 12, 2006.
Revised January 29, 2007.
Accepted for publication February 9, 2007.
Astrocyte death may occur in neurodegenerative disorders, and complicates the outcome of brain ischemia, a condition associated with high extracellular levels of adenosine and glutamate. We show that pharmacological activation of A1 adenosine and mGlu3 metabotropic glutamate receptors with N6-chlorocyclopentyladenosine (CCPA) and (-)2-oxa-4-aminocyclo-[3.1.0]hexane-4,6-dicarboxylic acid (LY379268), respectively, protects cultured astrocytes against apoptosis induced by a 3-hour exposure to oxygen/glucose deprivation (OGD). Protection by CCPA and LY379268 was less than additive and was abrogated by receptor blockade with selective competitive antagonists or pertussis toxin. Both in control astrocytes and in astrocytes exposed to OGD, CCPA and LY379268 induced a rapid activation of the phosphatidylinositol-3-kinase (PI3K) and extracellular signal-regulated kinases 1 and 2 (ERK1/2)/mitogen-activated protein kinase (MAPK) pathways, which are known to support cell survival. In cultures exposed to OGD, CCPA and LY379268 reduced the activation of c-Jun N-terminal kinase (JNK) and p38/MAPK, reduced the levels of the pro-apoptotic protein Bad, increased the levels of the anti-apoptotic protein Bcl-XL, and were highly protective against apoptotic death, as shown by nuclear DAPI staining and measurements of caspase 3 activity. All these effects were attenuated by treatment with U0126 and LY294002, which inhibit the MAPK and the PI3K pathways, respectively. These data suggest that pharmacological activation of A1 and mGlu3 receptors protects astrocytes against hypoxic/ischemic damage by stimulating the PI3K and ERK1/2 MAPK pathways.
Key words:
Adenosine, Metabotropic glutamate, Gi family, MAP Kinase, Jun Kinase, P38 MAP Kinase, Signaling network analyses, Receptor-mediated, Apoptosis, Ischemia/Reperfusion